Gland Pharma

BSE: 543245 | NSE: GLAND | ISIN: INE068V01023 | SECTOR: Biotechnology & Drugs

1,768.35

-23.40 (-1.31%)
18 May 2024, 12:29 PM IST

Key Metrics

Influencer Count

-

Simple Moving Averages

DaysBSENSE

51,774.111,775.20
101,739.821,740.97
201,740.051,741.13
501,760.611,761.48
1001,849.971,850.74
3001,732.281,732.76

News

Company Description

Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.

Company Officers